Target General Information |
Target ID |
T79068
|
Target Name |
Bacterial Enoyl-[acyl-carrier-protein] reductase [NADH] (Inha) |
Gene Name |
inhA |
Species |
Mycobacterium tuberculosis |
UniProt ID |
INHA_MYCTU |
Sequence |
MTGLLDGKRILVSGIITDSSIAFHIARVAQEQGAQLVLTGFDRLRLIQRITDRLPAKAPL LELDVQNEEHLASLAGRVTEAIGAGNKLDGVVHSIGFMPQTGMGINPFFDAPYADVSKGI HISAYSYASMAKALLPIMNPGGSIVGMDFDPSRAMPAYNWMTVAKSALESVNRFVAREAG KYGVRSNLVAAGPIRTLAMSAIVGGALGEEAGAQIQLLEEGWDQRAPIGWNMKDATPVAK TVCALLSDWLPATTGDIIYADGGAHTQLL [Mycobacterium tuberculosis]
|
Drug and Corresponding Resistance Mutations |
Mutation Info |
Missense: E217D |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[9] |
Targeted Disease |
Tuberculosis |
Mutation Prevalence |
1 out of 28 isolates |
|
Mutation Info |
Missense: I16T |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[2], [4] |
Targeted Disease |
Tuberculosis |
|
Mutation Info |
Missense: I194T |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[2], [5] |
Targeted Disease |
Tuberculosis |
Mutation Prevalence |
52 out of 102 isolates |
|
Mutation Info |
Missense: I21T |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[2], [3] |
Targeted Disease |
Tuberculosis |
|
Mutation Info |
Missense: I21V |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[2], [3] |
Targeted Disease |
Tuberculosis |
|
Mutation Info |
Missense: I47T |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[2], [4] |
Targeted Disease |
Tuberculosis |
|
Mutation Info |
Missense: I95P |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[2], [6] |
Targeted Disease |
Tuberculosis |
Mutation Prevalence |
7 out of 14 isolates |
|
Drug Name |
Ethionamide |
Drug Info
|
[6] |
Targeted Disease |
Tuberculosis |
Mutation Prevalence |
7 out of 14 isolates |
|
Mutation Info |
Missense: I95T |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[7] |
Targeted Disease |
Tuberculosis |
|
Mutation Info |
Missense: K8N |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[] |
Targeted Disease |
Tuberculosis |
|
Mutation Info |
Missense: R202G |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[9] |
Targeted Disease |
Tuberculosis |
Mutation Prevalence |
1 out of 28 isolates |
|
Mutation Info |
Missense: S94A |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[1], [2] |
Targeted Disease |
Tuberculosis |
|
Drug Name |
Ethionamide |
Drug Info
|
[1] |
Targeted Disease |
Tuberculosis |
|
Mutation Info |
Missense: S94L |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[8] |
Targeted Disease |
Tuberculosis |
|
Mutation Info |
Missense: V78A |
Drugs |
Drug Name |
Isoniazid |
Drug Info
|
[2], [4] |
Targeted Disease |
Tuberculosis |
|
References |
REF 1 |
Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int J Tuberc Lung Dis. 2000 May;4(5):441-7.
|
REF 2 |
CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 2017 Jan 4;45(D1):D566-D573.
|
REF 3 |
ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2003 Dec;47(12):3799-805.
|
REF 4 |
Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis. 1998 Sep;178(3):769-75.
|
REF 5 |
Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA. Antimicrob Agents Chemother. 2006 Mar;50(3):1075-8.
|
REF 6 |
New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains. Lancet. 1995 Aug 19;346(8973):502-3.
|
REF 7 |
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79(1):3-29.
|
REF 8 |
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med. 2006 Sep;12(9):1027-9.
|
REF 9 |
Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2009 Aug;47(8):2520-4.
|